National Registry and Cohort Study of Pulmonary Vascular Disease

NCT ID: NCT05368467

Last Updated: 2025-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-29

Study Completion Date

2028-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (PH). The purposes of this study were to evaluate the etiology、clinical characteristics、treatment modalities, and outcomes of patients with PH;also to set up registration system of PH in China, to build a database of Chinese PH, to establish a web-based international standard data acquisition system for PH and a multicenter clinical research platform. The results of the study will provide a basis for the future national health policy for prevention and treatment of PH.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

All consecutive consenting patients diagnosed with PH according to specific hemodynamic criteria at participating institutions.

The clinical course and disease management

Intervention Type COMBINATION_PRODUCT

The clinical course and disease management of pulmonary hypertension patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The clinical course and disease management

The clinical course and disease management of pulmonary hypertension patients

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed or previously diagnosed patients with PH.
* Documentation of mean pulmonary arterial pressure (mPAP) \>20 mm Hg by right heart catheterization, performed at any time prior to study enrollment.

Exclusion Criteria

* Have not had documentation of hemodynamic criteria for PH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PH.
* Do not meet the required hemodynamic criteria for entry into the study.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nanjing First Hospital, Nanjing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shaoliang Chen, MD

Vice President of Nanjing First Hospital, Director of Cardiovascular Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Guangdong Provincial Peoples Hospital

Guangzhou, Guangdong, China

Site Status RECRUITING

Nanjing First Hospital

Nanjing, Jiangsu, China

Site Status RECRUITING

General Hospital of Tianjin Medical University

Tianjin, Tianjin Municipality, China

Site Status RECRUITING

Beijing Anzhen Hospital of Capital Medical University

Beijing, , China

Site Status RECRUITING

China-japan Friendship Hospital

Beijing, , China

Site Status RECRUITING

Xiangya Second Hospital, Central South University

Changsha, , China

Site Status RECRUITING

West China Hospital, Sichuan University

Chendu, , China

Site Status RECRUITING

Nanjing Drum Tower Hospital

Nanjing, , China

Site Status RECRUITING

General Hospital of Northen Theater of Command

Shenyang, , China

Site Status RECRUITING

Tongji Hospital, Huazhong University of Science and Technology

Wuhan, , China

Site Status RECRUITING

Zhongnan Hospital of Wuhan University

Wuhan, , China

Site Status RECRUITING

First Affiliated Hospital of Xi'An Jiaotong University

Xi'an, , China

Site Status RECRUITING

First Hospital of Zhengzhou University

Zhengzhou, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shao-Liang Chen, MD, PhD

Role: CONTACT

+86-25-52271351

Jing Kan, MPH

Role: CONTACT

+86-25-52271398

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Caojing Zhang

Role: primary

Shaoliang Chen, MD

Role: primary

+86 13605157029

Zhenweng Yang

Role: primary

Hong Gu

Role: primary

zhenguo zhai

Role: primary

Jiang, Li

Role: primary

Yucheng, Chen

Role: primary

Jiaxin Ye

Role: primary

Qiguang Wang

Role: primary

Xiaomei Guo

Role: primary

Gangcheng Zhang

Role: primary

Fenling Fan

Role: primary

Heping Gu

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NMU20220505

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Novel Index (PIMR) in PAH
NCT05812976 COMPLETED